425
Filed by Validus Holdings, Ltd. pursuant to Rule 425
under the Securities Act of 1933, as amended,
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange of 1934, as amended
Subject Company: IPC Holdings, Ltd.
(Commission File No.: 000-27662)
(GRPAHICS)
Pro Forma Book Value Analysis April 5, 2009

 


 

(GRPAHICS)
Cautionary Note Regarding Forward-Looking Statements This presentation may include forward-looking statements, both with respect to us and our industry, that reflect our current views with respect to future events and financial performance. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “anticipate,” “will,” “may” and similar statements of a future or forward-looking nature identify forward-looking statements. All forward-looking statements address matters that involve risks and uncertainties. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in such statements and, therefore, you should not place undue reliance on any such statements. We believe that these factors include, but are not limited to, the following: 1) uncertainty as to whether IPC will enter into and consummate the proposed amalgamation on the terms set forth in our offer letter; 2) unpredictability and severity of catastrophic events; 3) rating agency actions; 4) adequacy of our risk management and loss limitation methods; 5) cyclicality of demand and pricing in the insurance and reinsurance markets; 6) our limited operating history; 7) our ability to successfully implement our business strategy during “soft” as well as “hard” markets; 8) adequacy of our loss reserves; 9) continued availability of capital and financing; 10) retention of key personnel; 11) competition; 12) potential loss of business from one or more major insurance or reinsurance brokers; 13) our ability to implement, successfully and on a timely basis, complex infrastructure, distribution capabilities, systems, procedures and internal controls, and to develop accurate actuarial data to support the business and regulatory and reporting requirements; 14) general economic and market conditions (including inflation, volatility in the credit and capital markets, interest rates and foreign currency exchange rates); 15) the integration of Talbot or other businesses we may acquire or new business ventures we may start; 16) the effect on our investment portfolio of changing financial market conditions including inflation, interest rates, liquidity and other factors; 17) acts of terrorism or outbreak of war; and 18) availability of reinsurance and retrocessional coverage, as well as management’s response to any of the aforementioned factors. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein or elsewhere, including the Risk Factors included in our most recent reports on Form 10-K and Form 10-Q and other documents on file with the Securities and Exchange Commission. Any forward-looking statements made in this release are qualified by these cautionary statements, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us or our business or operations. All forward-looking statements contained herein speak only as of the date of this presentation and we undertake no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. This presentation also contains unaudited proforma consolidated financial data intended to provide information about a potential amalgamation with IPC Holdings, Ltd. The unaudited proforma consolidated financial data does not necessarily reflect the financial position or results of operations that would have actually resulted had the amalgamation occurred as of the dates indicated, nor should they be taken as necessarily indicative of the future financial position or results of operati ons of the Company. Additional Information about the Proposed Transaction and Where to Find It: This material relates to a proposed business combination transaction between Validus and IPC which may become the subject of a registration statement and proxy statement filed by Validus with the SEC. This material is not a substitute for the registration statement and proxy statement that Validus would file with the SEC or any other documents which Validus may send to its or IPC’s shareholders in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. All such documents, if filed, would be available free of charge at the SEC’s website (www.sec.gov) Participants in the Solicitation: Validus and its directors, executive officers and other employees may be deemed to be participants in any solicitation of Validus shareholders in connection with the proposed transaction. Information about Validus’s directors and executive officers is available in Validus’s proxy statement, dated March 25, 2009 for its 2009 annual general meeting of shareholders. 1

 


 

(GRPAHICS)
Book Value Per Share Analysis Figures Presented By Max (1) Correct Pro Forma Numbers (2) Diluted Tangible Book Value Per IPC Share            Diluted Tangible Book Value Per IPC Share $40.00 $40.00 $33.83 $32.66 $28.93 $30.00 $26.19 $30.00 $20.00 $20.00 $10.00 $10.00 $0.00 $0.00 Max Validus            Max Validus Diluted Book Value Per IPC Share            Diluted Book Value Per IPC Share $40.00 $40.00 $34.93 $33.07 $30.05 $28.35 $30.00 $30.00 $20.00 $20.00 $10.00 $10.00 $0.00 $0.00 Max Validus            Max Validus Max’s Figures Are Incorrect (1) Max presentation from April 2, 2009 2 (2) Back-up on page 3-5 of presentation

 


 

(GRPAHICS)
Pro forma BVPS for IPCR — Validus Transaction IPCR Share IPCR Share ($ in 000s, actual shares) Translation @ Termination Translation @ IPCR Pro Rata VR IPCR 1.2037x Fee (12) Pro Forma 1.2037x Value Shares Outstanding Basic Shares 75,624,697 (1) 55,943,297 (9) 67,338,947 142,963,644 Warrants 8,680,149 (1) — - 8,680,149 Stock options 2,799,938 (1) 526,000 (10) 633,146 3,433,084 Unvested restricted shares 2,986,619 (1) 493,415 (10) 593,924 3,580,543 Diluted shares outstanding (2) 90,091,403 56,962,712 68,566,016 158,657,419 Book Value per Share Total shareholders’ equity $1,938,734 (1) $1,850,947 (11) $ (50,000) $3,739,681 Book value per share (3) $25.64 $33.09 $26.16 1.2037x $31.49 Diluted Book Value per Share Total shareholders’ equity $1,938,734 (1) $1,850,947 (11) $ (50,000) $3,739,681 Proceeds from exercise of Warrants (4) 152,316 152,316 Stock options (4) 51,043 18,047 69,090 Adjusted book value $2,142,093 $1,868,994 $3,961,087 Diluted book value per share (5) $23.78 $32.81 $24.97 1.2037x $30.05 Tangible Book Value per Share Total shareholders’ equity $1,938,734 (1) $1,850,947 (11) $ (50,000) $3,739,681 Goodwill and other intangible assets (147,610) (6) — (147,610) Total tangible shareholders’ equity 1,791,124 1,850,947 3,592,071 Tangible book value per share (7) $23.68 $33.09 $25.13 1.2037x $30.24 Diluted Tangible Book Value per Share Adjusted book value $2,142,093 $1,868,994 $3,961,087 Goodwill and other intangible assets (147,610) (6) — (147,610) Adjusted tangible book value $1,994,483 $1,868,994 $3,813,477 Diluted tangible book value per share (8) $22.14 $32.81 $24.04 1.2037x $28.93 Note: Excludes impact of purchase accounting adjustments except negative goodwill and $50 million termination fee charged against equity Endnotes on page 5 of presentation 3

 


 

(GRPAHICS)
Pro forma BVPS for IPCR — Max Transaction MXGL Share Translation @ Termination ($ in 000s, actual shares) IPCR MXGL 0.6429x Fee Pro Forma Shares Outstanding Shares 55,943,297 (9) 55,805,790 (13) 35,877,542 91,820,839 Warrants — 4,735,125 (14) 3,044,212 3,044,212 Stock options 526,000 (10) 1,843,263 (15) 1,185,034 1,711,034 Unvested restricted shares 493,415 (10) 2,468,826 (15) 1,587,208 2,080,623 Diluted shares outstanding (2) 56,962,712 64,853,004 41,693,996 98,656,708 Book Value per Share Total shareholders’ equity $1,850,947 (11) $1,280,331 (16) $3,131,278 Book value per share (3) $33.09 $22.94 $34.10 Diluted Book Value per Share Total shareholders’ equity $1,850,947 (11) $1,280,331 (16) $3,131,278 Proceeds from exercise of Warrants (4) - 72,589 72,589 Stock options (4) 18,047 40,994 59,041 Adjusted book value 1,868,994 1,393,915 3,262,909 Diluted book value per share (5) $32.81 $21.49 $33.07 Tangible Book Value per Share Total shareholders’ equity $1,850,947 (11) $1,280,331 (16) $3,131,278 Goodwill and other intangible assets — (40,488) (17) (40,488) Total tangible shareholders’ equity 1,850,947 1,239,843 3,090,790 Tangible book value per share (7) $33.09 $22.22 $33.66 Diluted Tangible Book Value per Share Adjusted book value $1,868,994 $1,393,915 $3,262,909 Goodwill and other intangible assets — (40,488) (17) (40,488) Adjusted tangible book value 1,868,994 1,353,427 3,222,421 Diluted tangible book value per share (8) $32.81 $20.87 $32.66 Note: Excludes impact of purchase accounting adjustments except negative goodwill Endnotes on page 5 of presentation 4

 


 

(GRPAHICS)
Endnotes Note: Excludes impact of purchase accounting adjustments except negative goodwill, and in the case of the Validus transaction, charging $50 million termination fee against equity 1) Page 6 of the Validus Investor Financial Supplement as of 12/31/2008 filed February 12, 2009 2) Gross amount of all warrants, options, restricted shares, RSUs, restricted common shares and performance share units outstanding as of the 12/31/2008 balance sheet date 3) Shareholders’ equity divided by common shares outstanding 4) Using the “as-if-converted” method, assuming all proceeds received upon exercise of warrants and stock options will be retained by the Company and the resulting common shares from exercise remain outstanding 5) Adjusted book value divided by diluted shares outstanding as of the 12/31/2008 balance sheet date 6) Validus Consolidated Balance Sheet per Page F-1 of the Validus 2008 Form 10-K filed 2/27/2009 7) Tangible shareholders’ equity divided by common shares outstanding as of the 12/31/2008 balance sheet date 8) Adjusted tangible book value divided by diluted shares outstanding as of the 12/31/2008 balance sheet date 9) Common shares outstanding as of 2/23/2009 per the front cover of the IPC Form 10—K filed 2/27/2009 10) Note 7 in the IPC 2008 Form 10-K filed 2/27/2009 Notes to the Consolidated Financial Statements 11) Per the IPC Consolidated Balance Sheet included in the IPC 2008 Form 10-K filed 2/27/2009 12) $50 million termination fee payable to Max 13) Common shares outstanding as of 12/31/08 per the MXGL Consolidated Balance Sheet contained within the Max 2008 Form 10-K filed 2/19/2009 14) Note 12 in the Max 2008 Form 10-K filed 2/19/2009 Notes to the Consolidated Financial Statements 15) Note 13 in the Max 2008 Form 10-K filed 2/19/2009 Notes to the Consolidated Financial Statements 16) Per the MXGL Consolidated Balance Sheet included in the 2008 Form 10-K filed 2/19/2009 17) Note 5 in the Max 2008 Form 10-K filed 2/19/2009 Notes to the Consolidated Financial Statements 5